Actualités Acerus Pharmaceuticals Corporation - ASP | Actions Toronto Stock Exchange

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Acerus Update

TORONTO, July 10, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company”) announces that...

Acerus Update

TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- As announced on January 26, 2023, Acerus Pharmaceuticals...

Acerus Announces Commencement of Court-Approved Sale and Investment Solicitation Process

TORONTO, March 14, 2023 (GLOBE NEWSWIRE) -- On January 26, 2023, Acerus Pharmaceuticals Corporation and...

Acerus Files For CCAA Protection

TORONTO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”...

Acerus Announces Resignation of Director

TORONTO, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”...

Acerus Announces New Loan Agreement With First Generation Capital

TORONTO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”...

Acerus Reports Third Quarter 2022 Financial Results

TORONTO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”...

Acerus Announces Amendment to Promissory Note Due to Former Serenity Shareholders

TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”...

Acerus Announces Initiation of Strategic Review

Ernst & Young Orenda Corporate Finance Inc. (“EY”) engaged as independent financial advisors TORONTO...

Acerus Announces Resignation of CFO Effective November 20, 2022

TORONTO, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”...

Acerus Reports Second Quarter 2022 Financial Results

TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”...

Acerus Announces Amendments to Loan Facility and Promissory Note Due to Former Serenity Shareholders

TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”...

Acerus to Report Q2-2022 Financial Results and Host Investor Call

TORONTO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will...

Acerus Announces Voting Results for the 2022 Annual Meeting

TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus”) (TSX: ASP; OTCQB:...

Acerus Announces Amendments to Loan Facility

TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Acerus Pharmaceuticals Corporation (ASP)

Outils de qualité professionnelle, pour des investisseurs individuels.

ASP Actualités

Acerus Update

Acerus Update

Acerus Announces Commencement of Court-Approved Sale and Investment Solicitation Process

Acerus Files For CCAA Protection

Acerus Announces Resignation of Director

Acerus Announces New Loan Agreement With First Generation Capital

Acerus Reports Third Quarter 2022 Financial Results

Acerus Announces Amendment to Promissory Note Due to Former Serenity Shareholders

Acerus Announces Initiation of Strategic Review

Acerus Announces Resignation of CFO Effective November 20, 2022

Acerus Reports Second Quarter 2022 Financial Results

Acerus Announces Amendments to Loan Facility and Promissory Note Due to Former Serenity Shareholders

Acerus to Report Q2-2022 Financial Results and Host Investor Call

Acerus Announces Voting Results for the 2022 Annual Meeting

Acerus Announces Amendments to Loan Facility

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Acerus Pharmaceuticals Corporation (ASP) Actualités

Acerus Pharmaceuticals Corporation (ASP)

Outils de qualité professionnelle, pour des investisseurs individuels.

ASP Actualités

Acerus Update

Acerus Update

Acerus Announces Commencement of Court-Approved Sale and Investment Solicitation Process

Acerus Files For CCAA Protection

Acerus Announces Resignation of Director

Acerus Announces New Loan Agreement With First Generation Capital

Acerus Reports Third Quarter 2022 Financial Results

Acerus Announces Amendment to Promissory Note Due to Former Serenity Shareholders

Acerus Announces Initiation of Strategic Review

Acerus Announces Resignation of CFO Effective November 20, 2022

Acerus Reports Second Quarter 2022 Financial Results

Acerus Announces Amendments to Loan Facility and Promissory Note Due to Former Serenity Shareholders

Acerus to Report Q2-2022 Financial Results and Host Investor Call

Acerus Announces Voting Results for the 2022 Annual Meeting

Acerus Announces Amendments to Loan Facility

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres